Studying Gene Expression in Samples From Patients With Rhabdoid Tumors

Completed

• Conditions: Kidney Cancer; Brain and Central Nervous System Tumors

• Registration Number: NCT01553175
• Lead Sponsor: Children's Oncology Group

Brief Summary

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and find biomarkers related to cancer. It may also help doctors find better ways to treat cancer.

PURPOSE: This research trial studies gene expression in samples from patients with rhabdoid tumors.

Detailed Description

OBJECTIVES:

* To determine if BRM is silenced in the majority, if not all, rhabdoid tumors by immunohistochemistry in primary tumors.

* To determine if BRG1 is silenced in the majority, if not all, rhabdoid tumors by immunohistochemistry in primary tumors.

* To determine if GATA1 and/or HDAC2 is overexpressed in the same tumors that lack BRM expression.

* To determine if BRM promoter polymorphisms correlate with loss of BRM expression in primary rhabdoid tumors.

* To determine how BRG1 is silenced in primary rhabdoid tumors by sequencing BRG1 exons in genomic DNA derived from frozen samples.

OUTLINE: Archived tumor tissue samples are analyzed for BRM, BRG1, GATA1, and/or HDAC2 expression by immunohistochemistry. BRM- and BRG1-negative samples are also analyzed.

Study Timeline

• Study Start: 2012-03
• Study First Submitted: 2012-03-10
• Study First Submitted QC: 2012-03-10
• Study First Posted: 2012-03-14
• Status Verified: 2016-07
• Primary Completion: 2016-07
• Last Update Submitted: 2016-07-13
• Last Update Posted: 2016-07-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Mechanism of suppression of BRG1 and BRM genes
Absence or presence BRG1 and BRM expression in rhabdoid tumors